Clinical Chemistry, Biochemistry of Lipids and Lab Instrumentation
Atherosclerosis; Lipoprotein; Inflammation, antioxidants, oxidative stress, cardiovascular diseases, reproductive medicine, fertility; In vitro fertilization, laboratory medicine & analytical method validation. Nutrition and Population Health
Atherosclerosis is a chronic disease in which modified lipid derivatives and cell infiltrations are mediated through a complex inflammatory process leading to plaque and tissue build up within the coronary arteries. This is the underlying cause of the majority of clinical cardiovascular events, which is the leading cause of death in the USA and around the world. Our Research Group focuses on the understanding of the role of lipids and its metabolites on atherosclerosis and lipoproteins metabolism. The group is also interested in obesity studies and the involvement of adipose biomarkers on atherosclerosis and other related chronic disorder. In addition the group is interested in studies on the role of indoor air pollution. The group research lab performs basic research experiments using cell culture, animal models and clinical studies. These studies involve dietary, antioxidants and therapeutic supplements targeting specific pathways of inflammation and oxidative stress. We are also interested in new clinical laboratory method development and validation.
Garelnabi received a Master of Science in Clinical Biochemistry from Bombay University and a doctoral degree in Clinical Biochemistry from Delhi University, India. He joined a postdoctoral fellowship in cardiovascular disease and lipoprotein pathophysiology at Emory University; and later joined The Ohio State University as a research scientist. He briefly joined Siemens Healthcare Diagnostic as a Senior Scientist at the Department of Medical and Clinical Affairs before join the University of Massachusetts. Presently Garelnabi is an Associate Professor at the department of Biomedical and Nutritional Sciences, University of Massachusetts Lowell. Garelnabi authored several scientific articles and book chapters and presented his research work at National and International meetings. He is an editorial board member and a reviewer for several scientific journals. In addition; Garelnabi is an active member and contributor to many scientific and professional organizations including the American Heart Association council of Atherosclerosis, Thrombosis and vascular Biology; the American Association for Clinical Chemistry, the National Lipids Association and the European Atherosclerosis Society.